أرسل هذا في رسالة قصيرة: Will the requirement by the US FDA to simultaneously co-develop companion diagnostics (CDx) delay the approval of receptor tyrosine kinase inhibitors for RTK-rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) non-small cell lung cancer globally?

 __   __   __   __               ___      _____   
 \ \\/ //  \ \\/ //   ____      / _ \\   /  ___|| 
  \   //    \ ` //   |    \\   / //\ \\ | // __   
  / . \\     | ||    | [] ||  |  ___  ||| \\_\ || 
 /_//\_\\    |_||    |  __//  |_||  |_|| \____//  
 `-`  --`    `-`'    |_|`-`   `-`   `-`   `---`   
                     `-`